- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why | 2 | Zacks | ||
| 25.03. | Apogee Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | 87 | GlobeNewswire (Europe) | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
| 12.03. | Apogee Therapeutics, Inc.: Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million | 2 | GlobeNewswire (USA) | ||
| 08.03. | Apogee Therapeutics stock slides on pricing upsized stock offering to raise $420 million | 2 | Seeking Alpha | ||
| 08.03. | Apogee Therapeutics Prices Upsized Public Offering Of About 6.77 Mln Shares At $62.00/shr | 1 | RTTNews | ||
| 08.03. | Apogee Therapeutics, Inc.: Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering | 1 | GlobeNewswire (USA) | ||
| 05.03. | Apogee Therapeutics plans $350 million stock offering | 2 | Investing.com | ||
| 05.03. | Apogee Therapeutics, Inc.: Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering | 1 | GlobeNewswire (USA) | ||
| 05.03. | Apogee Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.03. | Stifel raises Apogee Therapeutics stock target to $95, maintains buy | 3 | Investing.com | ||
| 05.03. | Apogee data hint at potential for long-lasting eczema drug | 4 | BioPharma Dive | ||
| 05.03. | Apogee Therapeutics hits record high on positive data for skin disease drug | 4 | Reuters | ||
| 05.03. | US STOCKS Apogee Therapeutics ,Target, Enviva | 34 | Reuters | ||
| 05.03. | Pre-market Movers: CASI Pharmaceuticals, QT Imaging, Apogee Therapeutics, Quoin Pharmaceuticals, Phunware | 399 | AFX News | MINNEAPOLIS (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.10 A.M. ET).In the Green CASI Pharmaceuticals, Inc. (CASI) is up over... ► Artikel lesen | |
| 05.03. | Apogee Therapeutics rises on positive data for skin disease drug | 4 | Reuters | ||
| 05.03. | Apogee Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 05.03. | Apogee Therapeutics, Inc.: Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results | 61 | GlobeNewswire (Europe) | Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to potential... ► Artikel lesen | |
| 05.03. | Apogee Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.03. | Apogee Therapeutics, Inc.: Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases | 340 | GlobeNewswire (Europe) | Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintenance... ► Artikel lesen |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,860 | +1,18 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,860 | +10,30 % | Looking Into Ginkgo Bioworks Holdings' Recent Short Interest | ||
| BEAM THERAPEUTICS | 21,360 | -1,11 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,010 | -1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,550 | +1,45 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,828 | +5,49 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,790 | +1,74 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,230 | +7,86 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | -1,29 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,350 | +3,21 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,680 | +1,71 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,780 | +2,96 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen APOGEE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,77 % bei einem Aktienkurs von 47,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
